• 1,584.00

     Indications: Prescribed for treatment of Angina pectoris. Dosage:  Adult : PO 40-60 mg/day in divided doses. Modified-release tab: 35 mg bid. Contraindications: Parkinson’s disease, parkinsonian symptoms, tremors, restless leg syndrome and other movement related disorders. Severe renal impairment (CrCl <30 mL/min). Lactation. Special precautions: Moderate renal impairment (CrCl 30-60 mL/min). Pregnancy. Adverse drug reactions: Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, nausea, vomiting, pruritus, rash, urticaria, asthenia. Rarely, tachycardia, palpitations, extrasystoles, orthostatic hypotension, arterial hypotension, flushing.  Drug Interactions:  Trimetazidine is a drug for angina pectoris sold under the brand name Vastarel MR. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation. High fatty acid oxidation rates are detrimental during ischemia due to an inhibition of glucose oxidation leading to uncoupling of glycolysis and an increase in proton production, which has the potential to accelerate sodium and calcium overload in the heart, which leads to an exacerbation of ischemic injury and decreased cardiac efficiency during reperfusion. Overdosage:  Trimetazidine Overdose side effect reports were submitted by healthcare professionals and consumers. Mechanism of action: Trimetazidine inhibits β-oxidation of fatty acids through inhibition of long-chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation. It ensures proper functioning of ionic pumps and transmembrane Na-K flow by preventing decrease in intracellular ATP levels.

  • 277.20

    Losartan Hydrochlorothiazide is used for treatment of hypertension.